The human hepatoma Hep3B cell line as an experimental model in the study of the long-term regulation of acute-phase proteins by cytokines.
The regulation of the synthesis by the cytokines interleukin-1 (IL-1) and IL-6 of the positive acute-phase protein alpha 1-acid glycoprotein (AGP) and of the negative acute-phase protein alpha 2-HS glycoprotein (AHSG) has been studied in a long-term culture system of the human hepatoma cell line Hep3B. The culture system contained 30 nM-sodium selenite as the only supplement. This allowed maintenance of the synthesis of the proteins under study at a near steady state for over 3 months. An increase in AGP mRNA and a decrease in AHSG mRNA were observed when cells were treated for two successive 48 h-periods with monocyte-conditioned medium. A return to basal levels was obtained after cessation of the cytokine addition. Two further additions of cytokines led to alterations in mRNA levels similar to those observed following the first cytokine treatment. The amounts of AGP and AHSG secreted were altered in accordance with the mRNA modifications. These results suggest that new cytokine receptors were being constantly synthesized during cell culture. When cytokines were present in the culture medium for 10 days, maximum alterations in AGP and AHSG synthesis were obtained following 2 and 4 days of treatment respectively, but further alterations in protein levels could not be observed afterwards. Expression of IL-6 receptor mRNA was not up-regulated by cytokines, but only by 1 microM-dexamethasone. Our results show that, in this long-term culture system, cytokines induce a response in hepatoma cells similar to that observed in vivo during human inflammatory states. This model could be used to evaluate the effects of agonists or antagonists of cytokines responsible for the hepatic acute-phase protein response.
Hiron
M
M
Institut National de la Santé et de la Recherche, Médicale Unité 78, Bois-Guillaume, France.
Daveau
M
M
Arnaud
P
P
Bauer
J
J
Lebreton
J P
JP
D000209:Acute-Phase Proteins / Q000378:metabolism*; D000210:Acute-Phase Reaction; D001798:Blood Proteins / Q000235:genetics; D016207:Cytokines / Q000502:physiology*; D015870:Gene Expression; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D008099:Liver / Q000378:metabolism*; D009961:Orosomucoid / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D011971:Receptors, Immunologic / Q000235:genetics; D019947:Receptors, Interleukin-6; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000378:metabolism*; D060749:alpha-2-HS-Glycoprotein
C556354:AHSG protein, human; D000209:Acute-Phase Proteins; D001798:Blood Proteins; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D009961:Orosomucoid; D012333:RNA, Messenger; D011971:Receptors, Immunologic; D019947:Receptors, Interleukin-6; D060749:alpha-2-HS-Glycoprotein